Endo Whistleblower Gets 24% Cut Of $140M FCA Deal
The whistleblower who alerted the government to Endo Pharmaceuticals Inc.'s off-label marketing of the pain-relief patch Lidoderm won 24 percent of a $140 million False Claims Act settlement Wednesday, with a...To view the full article, register now.
Already a subscriber? Click here to view full article